Imaging Endpoints announced today that the Company is well prepared for the business implications of the COVID-19 pandemic. Imaging Endpoints (IE) has implemented a Wellness Policy with strict protections for its workforce and has moved many of its staff to work from home. IE believes it may have the most modern and unique cloud-based infrastructure in the iCRO industry, and its global workforce (including its 97 physician readers) is able to work from home with the same reliability and efficiency as when in the office. Based on the recommendations from “FDA’s Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic” the Company has prepared contingency plans as appropriate to assist with its clients’ with clinical site challenges during the pandemic.
In addition, IE is offering a Coronavirus specific image analysis platform with advanced analysis capabilities for Sponsors who would benefit. The Company will also provide complementary COVID-19 analysis services on incoming CTs, and is engaged in radiomic research to improve the sensitivity and specificity of COVID-19 detection on CT as well as to develop a rapid, non-invasive assessment to risk stratify which patients will go on to require respiratory mechanical support.